Cargando…
Clinical investigation of a unique type of hypothalamic adrenal insufficiency
Hypothalamic adrenal insufficiency (AI) is a rare but distinct type of AI. The leading cause of hypothalamic AI is a secondary side-effect of exogenous steroid intake, particularly in large amounts and/or long-term periods. The next cause would be the effect of the tumor in the hypothalamic lesions....
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575774/ https://www.ncbi.nlm.nih.gov/pubmed/36253985 http://dx.doi.org/10.1097/MD.0000000000030597 |
_version_ | 1784811384862670848 |
---|---|
author | Takeshita, Kaori Abe, Ichiro Nagata, Mai Ochi, Kentaro Senda, Yuki Koga, Midori Ohe, Kenji Abe, Makiko Kudo, Tadachika Kobayashi, Kunihisa |
author_facet | Takeshita, Kaori Abe, Ichiro Nagata, Mai Ochi, Kentaro Senda, Yuki Koga, Midori Ohe, Kenji Abe, Makiko Kudo, Tadachika Kobayashi, Kunihisa |
author_sort | Takeshita, Kaori |
collection | PubMed |
description | Hypothalamic adrenal insufficiency (AI) is a rare but distinct type of AI. The leading cause of hypothalamic AI is a secondary side-effect of exogenous steroid intake, particularly in large amounts and/or long-term periods. The next cause would be the effect of the tumor in the hypothalamic lesions. We show here 9 cases of hypothalamic AI without any disorder on imagings and a history of steroid administration. All patients had general fatigue; 7 patients (77.8%) had a history of hypoglycemia; 5 patients (55.6%) had a history of hypotension. None of the patients had hyponatremia, hyperkalemia, or eosinophilia. Their morning plasma adrenocorticotropic hormone (ACTH) value was low at 8.5 ± 4.2 pg/mL, and serum cortisol value was low at 4.5 ± 1.3 µg/dL. All patients demonstrated normal responses during the corticotropin-releasing hormone loading (CRH) test but inadequate responses during the insulin tolerance test (ITT). After hydrocortisone replacement therapy, their morning plasma ACTH and serum cortisol values were significantly recovered (P < .05). Moreover, more than half of the patients were fine after discontinuing hydrocortisone replacement therapy. These results indicate that this unique type of hypothalamic AI has a curable clinical course making hydrocortisone replacement therapy a novel therapeutic option. |
format | Online Article Text |
id | pubmed-9575774 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-95757742022-10-17 Clinical investigation of a unique type of hypothalamic adrenal insufficiency Takeshita, Kaori Abe, Ichiro Nagata, Mai Ochi, Kentaro Senda, Yuki Koga, Midori Ohe, Kenji Abe, Makiko Kudo, Tadachika Kobayashi, Kunihisa Medicine (Baltimore) 4300 Hypothalamic adrenal insufficiency (AI) is a rare but distinct type of AI. The leading cause of hypothalamic AI is a secondary side-effect of exogenous steroid intake, particularly in large amounts and/or long-term periods. The next cause would be the effect of the tumor in the hypothalamic lesions. We show here 9 cases of hypothalamic AI without any disorder on imagings and a history of steroid administration. All patients had general fatigue; 7 patients (77.8%) had a history of hypoglycemia; 5 patients (55.6%) had a history of hypotension. None of the patients had hyponatremia, hyperkalemia, or eosinophilia. Their morning plasma adrenocorticotropic hormone (ACTH) value was low at 8.5 ± 4.2 pg/mL, and serum cortisol value was low at 4.5 ± 1.3 µg/dL. All patients demonstrated normal responses during the corticotropin-releasing hormone loading (CRH) test but inadequate responses during the insulin tolerance test (ITT). After hydrocortisone replacement therapy, their morning plasma ACTH and serum cortisol values were significantly recovered (P < .05). Moreover, more than half of the patients were fine after discontinuing hydrocortisone replacement therapy. These results indicate that this unique type of hypothalamic AI has a curable clinical course making hydrocortisone replacement therapy a novel therapeutic option. Lippincott Williams & Wilkins 2022-10-14 /pmc/articles/PMC9575774/ /pubmed/36253985 http://dx.doi.org/10.1097/MD.0000000000030597 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. |
spellingShingle | 4300 Takeshita, Kaori Abe, Ichiro Nagata, Mai Ochi, Kentaro Senda, Yuki Koga, Midori Ohe, Kenji Abe, Makiko Kudo, Tadachika Kobayashi, Kunihisa Clinical investigation of a unique type of hypothalamic adrenal insufficiency |
title | Clinical investigation of a unique type of hypothalamic adrenal insufficiency |
title_full | Clinical investigation of a unique type of hypothalamic adrenal insufficiency |
title_fullStr | Clinical investigation of a unique type of hypothalamic adrenal insufficiency |
title_full_unstemmed | Clinical investigation of a unique type of hypothalamic adrenal insufficiency |
title_short | Clinical investigation of a unique type of hypothalamic adrenal insufficiency |
title_sort | clinical investigation of a unique type of hypothalamic adrenal insufficiency |
topic | 4300 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575774/ https://www.ncbi.nlm.nih.gov/pubmed/36253985 http://dx.doi.org/10.1097/MD.0000000000030597 |
work_keys_str_mv | AT takeshitakaori clinicalinvestigationofauniquetypeofhypothalamicadrenalinsufficiency AT abeichiro clinicalinvestigationofauniquetypeofhypothalamicadrenalinsufficiency AT nagatamai clinicalinvestigationofauniquetypeofhypothalamicadrenalinsufficiency AT ochikentaro clinicalinvestigationofauniquetypeofhypothalamicadrenalinsufficiency AT sendayuki clinicalinvestigationofauniquetypeofhypothalamicadrenalinsufficiency AT kogamidori clinicalinvestigationofauniquetypeofhypothalamicadrenalinsufficiency AT ohekenji clinicalinvestigationofauniquetypeofhypothalamicadrenalinsufficiency AT abemakiko clinicalinvestigationofauniquetypeofhypothalamicadrenalinsufficiency AT kudotadachika clinicalinvestigationofauniquetypeofhypothalamicadrenalinsufficiency AT kobayashikunihisa clinicalinvestigationofauniquetypeofhypothalamicadrenalinsufficiency |